Title :

Prospective phase ii study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome

Author(s) :

Guillaume, Thierry [Auteur]
Centre de Recherche en Cancérologie Nantes-Angers [CRCNA]
Malard, Florent [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Magro, Leonardo [Auteur]
Labopin, Myriam [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Tabrizi, Reza [Auteur]
Borel, Cecile [Auteur]
Chevallier, Patrice [Auteur]
Centre de Recherche en Cancérologie Nantes-Angers [CRCNA]
Vigouroux, Stephane [Auteur]
Peterlin, Pierre [Auteur]
Garnier, Alice [Auteur]
Rubio, Marie-Therese [Auteur]
Huynh, Anne [Auteur]
Milpied, Noel [Auteur]
Moreau, Philippe [Auteur]
Centre de Recherche en Cancérologie Nantes-Angers [CRCNA]
Gaugler, Beatrice [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Mohty, Mohamad [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]

Journal title :

Bone Marrow Transplantation

Abbreviated title :

Bone Marrow Transplant.

Volume number :

54

Pages :

1815–1826

Publication date :

2019-11

ISSN :

1476-5365

English keyword(s) :

azacitidine
relapse prevention
donor lymphocyte infusion

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Thirty patients, with high-risk acute myeloid leukemia (AML, n = 20) or myelodysplastic syndrome (MDS, n = 10), were enrolled in a phase II trial entailing prophylactic post-transplant azacitidine (AZA) plus escalated doses ...
Show more >Thirty patients, with high-risk acute myeloid leukemia (AML, n = 20) or myelodysplastic syndrome (MDS, n = 10), were enrolled in a phase II trial entailing prophylactic post-transplant azacitidine (AZA) plus escalated doses of donor lymphocyte infusion (DLI). The median number of AZA cycles was 5 (1-12) with 10 patients (33%) completing the 12 projected cycles. DLI were performed in 17 patients: 5 received one DLI, 2 received 2 DLI and 8 received 3 infusions. AZA was well tolerated, but discontinued in 20 patients primarily due to graft-versus-host disease (GvHD) and relapse. The cumulative incidence (CI) of grade 1-3 acute GvHD was 31.5% and the chronic GvHD CI was 53% at 2 years. At a median follow-up of 49 months (27-63), 18 patients are alive. The overall and disease-free survivals are 65.5% (CI 95% = 48.2-82.8) at 2 years. Cause of death was mainly relapse for 9 patients. The median time to relapse was 7 months (2.5-58) and the cumulative incidence of relapse at 2 years was 27.6% (CI 95% = 12.8-44.6). These results confirm that AZA is well tolerated as a prophylactic treatment to reduce the risk of post-transplantation relapse and compared favorably to those of patients who receive no post-transplant maintenance.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-30T10:28:02Z
2024-01-31T14:02:55Z